<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148894" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Familial Combined Hyperlipidemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fabian</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>Guthrie Robert Packer Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Johal</surname>
            <given-names>Gurpreet S.</given-names>
          </name>
          <aff>University of Washington - Valley Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Fabian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gurpreet Johal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148894.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Familial combined hyperlipidemia (FCH) is a hereditary metabolic disorder characterized by elevated levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and decreased levels of high-density lipoprotein (HDL) cholesterol. FCH is one of the most common hereditary lipid disorders. In addition, this disease is associated with an increased risk of developing cardiovascular disease, including atherosclerosis and coronary heart disease. Despite its prevalence and potential health consequences, FCH is often underdiagnosed and undertreated, making it a topic of ongoing research to understand its underlying genetic and metabolic mechanisms better and develop effective treatment strategies. This activity reviews the etiology, pathophysiology, evaluation, and management of familial combined hyperlipidemia. It also examines the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at risk of familial combined hyperlipidemia through comprehensive medical history, physical examination, and familial screening.</p></list-item><list-item><p>Assess lipid profiles, including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol levels, at regular intervals to monitor disease progression and treatment effectiveness.</p></list-item><list-item><p>Apply pharmacological and non-pharmacological interventions to control lipid levels and mitigate the risk of cardiovascular complications.</p></list-item><list-item><p>Communicate effectively with patients, families, and other healthcare team members to ensure a clear understanding of the diagnosis, treatment goals, and follow-up plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148894&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148894">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148894.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Familial combined hyperlipidemia (FCH) is a common and prevalent hereditary lipid disorder. The inherited primary dyslipidemia is named after its variable expression of increased plasma cholesterol and triglyceride levels, which affects at least two family members.<xref ref-type="bibr" rid="article-148894.r1">[1]</xref> In 1973, FCH was initially described as an autosomal dominant inherited lipid disorder by Goldstein <italic toggle="yes">et al</italic>, Rose <italic toggle="yes">et al</italic>, and Nikkila <italic toggle="yes">et al.</italic> However, it was later found to have a multigenic mode and complex inheritance.<xref ref-type="bibr" rid="article-148894.r2">[2]</xref><xref ref-type="bibr" rid="article-148894.r3">[3]</xref></p>
        <p>FCH&#x000a0;manifests as increased serum cholesterol levels (hypercholesterolemia) and/or increased triglycerides (hypertriglyceridemia).<xref ref-type="bibr" rid="article-148894.r4">[4]</xref>&#x000a0;It may also present as isolated increases in apolipoprotein B&#x000a0;(apoB) with a serum lipid profile in the reference range.<xref ref-type="bibr" rid="article-148894.r4">[4]</xref> The estimated prevalence of&#x000a0;FCH is approximately 0.5 to 4%.<xref ref-type="bibr" rid="article-148894.r5">[5]</xref>&#x000a0;The genetic element of FCH has not been fully understood to date.<xref ref-type="bibr" rid="article-148894.r6">[6]</xref>&#x000a0;Associated metabolic dysfunction includes increased very low-density lipoprotein (VLDL) and slowed removal of low-density (LDL) and triglyceride-rich lipoproteins.<xref ref-type="bibr" rid="article-148894.r6">[6]</xref>&#x000a0;</p>
        <p>The abnormal increases in plasma lipids and triglycerides are significant risk factors for cardiovascular disease (CVD) and CVD-related mortality. The risk for mortality increases in individuals with underlying metabolic comorbidities such as type 2 diabetes (T2DM), obesity, alcohol dependence, hypothyroidism, and liver disease.<xref ref-type="bibr" rid="article-148894.r4">[4]</xref> FCH is most commonly seen as an underlying risk factor in individuals with coronary heart disease and patients with acute myocardial infarction.<xref ref-type="bibr" rid="article-148894.r7">[7]</xref></p>
        <p>The management of FCH patients includes therapeutic agents to lower cholesterol and triglyceride levels to prevent cardiovascular disease. FDA-approved treatments include HMG-CoA reductase inhibitors (statins),&#x000a0;fibric acid derivatives (fibrates), bile acid sequestrants,&#x000a0;PCSK9 inhibitors, niacin, and ezetimibe.<xref ref-type="bibr" rid="article-148894.r8">[8]</xref><xref ref-type="bibr" rid="article-148894.r9">[9]</xref>&#x000a0;Other treatment options include&#x000a0;omega-3 fatty acids (fish oil) and&#x000a0;MTTP inhibitors (lomitapide).</p>
      </sec>
      <sec id="article-148894.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>As previously stated, the genetic element of FCH has not been fully understood to date.<xref ref-type="bibr" rid="article-148894.r6">[6]</xref> The pattern of inheritance of FCH was initially reported to be autosomal dominant in 1973 by Goldstein et al.<xref ref-type="bibr" rid="article-148894.r2">[2]</xref> Later research specified and proposed that FCH be familial or nonfamilial, making it a multigenic mode and complex inheritance.<xref ref-type="bibr" rid="article-148894.r2">[2]</xref><xref ref-type="bibr" rid="article-148894.r3">[3]</xref>&#x000a0;</p>
        <p>Alongside the hereditary aspect of FCH, other risk factors contributing to the pathogenesis include environmental elements.<xref ref-type="bibr" rid="article-148894.r3">[3]</xref> The pathophysiologic mechanisms of FCH result in metabolic dysfunction, causing increased very low-density lipoprotein (VLDL), slowed removal of low-density (LDL) and triglyceride-rich lipoproteins, and unregulated overproduction of apo-B lipoproteins in the liver.<xref ref-type="bibr" rid="article-148894.r6">[6]</xref><xref ref-type="bibr" rid="article-148894.r3">[3]</xref></p>
      </sec>
      <sec id="article-148894.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The estimated prevalence of&#x000a0;FCH is approximately 0.5% to 4%.<xref ref-type="bibr" rid="article-148894.r5">[5]</xref>&#x000a0;Roughly 10% to 20% of individuals who have experienced premature myocardial infarction are found to have familial combined hyperlipidemia.<xref ref-type="bibr" rid="article-148894.r10">[10]</xref> According to a study conducted by Paramsothy et al in 2009, the prevalence of combined hyperlipidemia demonstrates variation among different racial groups. The study found that Hispanics exhibited higher rates of combined hyperlipidemia compared to whites. Conversely, African-Americans had lower rates of combined hyperlipidemia than whites, despite having higher body mass index levels and abdominal adiposity. This suggests that African-Americans have lower odds of developing combined hyperlipidemia when compared to individuals of white ethnicity.<xref ref-type="bibr" rid="article-148894.r11">[11]</xref></p>
      </sec>
      <sec id="article-148894.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Familial combined hyperlipidemia is believed to be caused by an underlying pathophysiological mechanism characterized by hepatic overproduction of lipoprotein particles containing apoB-100, namely VLDL and LDL. This results in elevated levels of plasma total cholesterol, triglycerides, and apoB. Furthermore, individuals with FCH exhibit reduced HDL cholesterol levels and an increase in small dense LDL (sdLDL) and remnant lipoprotein particles.<xref ref-type="bibr" rid="article-148894.r12">[12]</xref>&#x000a0;</p>
        <p>Initially, it was believed that FCH was inherited through a dominant monogenic manner. However, subsequent studies proposed a more complex polygenic inheritance to explain the variability in the lipid phenotype. Several loci, specifically at 9p, 16q, and 11q, have been linked to LDL size in FCH patients.<xref ref-type="bibr" rid="article-148894.r13">[13]</xref>&#x000a0;Notably, the gene encoding Upstream Transcription Factor 1 (USF1) has been associated with FCH. USF1 regulates various genes related to glucose and lipid metabolism.<xref ref-type="bibr" rid="article-148894.r14">[14]</xref><xref ref-type="bibr" rid="article-148894.r15">[15]</xref></p>
        <p>Patients with FCH are noted to have delayed clearance of chylomicron and VLDL remnants.<xref ref-type="bibr" rid="article-148894.r16">[16]</xref>&#x000a0;One of the genes involved in their clearance pathways is the LPL gene.<xref ref-type="bibr" rid="article-148894.r17">[17]</xref>&#x000a0;A recent study has linked a mutation that substitutes aspartic acid with asparagine at position 151 in the LPL gene to an increased incidence of FCH.<xref ref-type="bibr" rid="article-148894.r18">[18]</xref></p>
        <p>Impairment in the low-density lipoprotein receptor (LDLR) can increase LDL levels. Mutations in the LDLR may lead to FCH.<xref ref-type="bibr" rid="article-148894.r19">[19]</xref>&#x000a0;Proprotein convertase subtilisin kexin type 9 (PCSK9) is associated with the cholesterol synthesis markers lathosterol and desmosterol. PSCK9 levels are also a stimulus for LDLR degradation. A study by Brouwers et al demonstrated that PCSK9 levels are heritable and increased in patients with FCH.<xref ref-type="bibr" rid="article-148894.r20">[20]</xref></p>
      </sec>
      <sec id="article-148894.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with familial combined hyperlipidemia often have a family history of dyslipidemia, premature cardiovascular disease, and premature death from heart disease or stroke. Aside from the positive familial history, FCH patients may exhibit symptoms such as chest discomfort, difficulty breathing, or leg pain while walking. Additionally, they may possess risk factors for cardiovascular conditions, such as hypertension, diabetes, and obesity.<xref ref-type="bibr" rid="article-148894.r21">[21]</xref></p>
        <p>FCH is a complex disorder with variable expression and penetrance, and the age of onset and severity of symptoms can differ among affected individuals within the same family. Therefore, obtaining a detailed family history of hyperlipidemia, cardiovascular disease, and premature death is crucial, especially among first-degree relatives.&#x000a0;</p>
        <p>The physical examination of a patient with FCH is typically unremarkable, with no specific physical findings associated with the disorder. However, patients with FCH may have signs of cardiovascular disease such as hypertension, peripheral arterial disease (PAD), or carotid bruits. Though they are rare in patients with FCH, a careful examination of the skin may reveal the presence of xanthomas. These cholesterol deposits are often associated with high cholesterol levels or triglycerides in the blood. They may indicate an underlying metabolic disorder such as familial combined hyperlipidemia or familial hypercholesterolemia.<xref ref-type="bibr" rid="article-148894.r22">[22]</xref><xref ref-type="bibr" rid="article-148894.r23">[23]</xref></p>
        <p>Furthermore, a comprehensive cardiac assessment may detect the existence of a murmur, indicating potential valvular heart disease, or indications of heart failure, such as peripheral edema, jugular venous distension, and hepatomegaly. A neurological examination may reveal the presence of focal deficits, suggesting cerebrovascular disease.</p>
      </sec>
      <sec id="article-148894.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Familial combined hyperlipidemia can present with varying laboratory findings in different individuals and members of the same family. The laboratory results may reveal elevated levels of serum triglycerides, total cholesterol, mixed triglycerides, increased very-low-density lipoproteins (VLDLs), increased low-density lipoproteins (LDLs), raised levels of apolipoprotein B (apo-B), or reduced levels of high-density lipoprotein (HDL).<xref ref-type="bibr" rid="article-148894.r7">[7]</xref>&#x000a0;Elevations in triglycerides and apo-B may exhibit values of 1.5 mmol/L and 1.2 g/L, respectively.<xref ref-type="bibr" rid="article-148894.r1">[1]</xref>&#x000a0;</p>
        <p>Several studies have reported an association between FCH and increased carotid intima-media thickness (IMT), a marker of subclinical atherosclerosis. Therefore, a carotid ultrasound may be performed to assess the presence of subclinical atherosclerosis in patients with FCH.<xref ref-type="bibr" rid="article-148894.r24">[24]</xref><xref ref-type="bibr" rid="article-148894.r25">[25]</xref></p>
      </sec>
      <sec id="article-148894.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Familial combined hyperlipidemia, the most commonly reported genetic dyslipidemia, increases the risk of early atherosclerosis expression.<xref ref-type="bibr" rid="article-148894.r1">[1]</xref> The management of FCH surrounds reducing&#x000a0;the increased lipid levels in circulation within the reference range and routine monitoring to decrease premature cardiovascular disease.&#x000a0;The management of FCH is similar to other dyslipidemias, which include pharmacologic therapies and lifestyle changes such as diet and exercise.<xref ref-type="bibr" rid="article-148894.r26">[26]</xref></p>
        <p>FDA-approved treatments include HMG-CoA reductase inhibitors (statins), fibric acid derivatives (fibrates), bile acid sequestrants, PCSK9 inhibitors, adenosine triphosphate-citrate lyase inhibitors (bempedoic acid), niacin and ezetimibe.<xref ref-type="bibr" rid="article-148894.r8">[8]</xref><xref ref-type="bibr" rid="article-148894.r9">[9]</xref>&#x000a0;Other treatment options include omega-3 fatty acids (fish oil) and MTTP inhibitors (lomitapide).</p>
        <p>
<bold>Statins</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atorvastatin</p>
          </list-item>
          <list-item>
            <p>Fluvastatin</p>
          </list-item>
          <list-item>
            <p>Lovastatin</p>
          </list-item>
          <list-item>
            <p>Pravastatin</p>
          </list-item>
          <list-item>
            <p>Rosuvastatin</p>
          </list-item>
          <list-item>
            <p>Simvastatin</p>
          </list-item>
          <list-item>
            <p>Pitavastatin<xref ref-type="bibr" rid="article-148894.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>Statins exert their mechanism of action by&#x000a0;inhibiting the HMG-CoA reductase enzyme in the hepatocytes, further causing the decreased&#x000a0;intracellular synthesis of cholesterol. HMG-CoA reductase is the rate-limiting step in the mevalonate pathway responsible for cholesterol synthesis.<xref ref-type="bibr" rid="article-148894.r28">[28]</xref>&#x000a0;The hepatic LDL receptors have a high affinity for LDL and VLDL particles, further causing endocytosis in the liver. Following binding, the cholesterol is mixed with bile salts and excreted as a waste product or recycled, reducing circulating serum cholesterol.</p>
        <p>The majority of cholesterol in circulation is produced by internal hepatic synthesis relative to dietary intake, making statins a prevalently used agent in hyperlipidemia and dyslipidemia. The primary therapeutic goal of statins is to lower levels of low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), triglycerides (TG), apolipoprotein B (apo-B) lipoprotein, and total cholesterol, while simultaneously increasing levels of high-density lipoprotein cholesterol (HDL-C).<xref ref-type="bibr" rid="article-148894.r27">[27]</xref></p>
        <p>
<bold>Fibrates</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gemfibrozil</p>
          </list-item>
          <list-item>
            <p>Fenofibrate</p>
          </list-item>
          <list-item>
            <p>Fenofibric acid<xref ref-type="bibr" rid="article-148894.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>Fibric acids exert mechanistic effects by stimulating peroxisome proliferator-activated alpha (PPAR-a) receptors. Following the binding of the ligand to its target transcriptional factor PPAR-a receptors, it further causes downstream effects and activation of multiple biological processes.&#x000a0;The therapeutic action of fibrates is mainly through the beta-oxidation of fatty acids and the metabolism of lipids in circulation, making it effective in hypercholesterolemia and hypertriglyceridemia. This further reduces TG particles and aids in the breakdown of VLDL.&#x000a0;This helps decrease the atherosclerotic burden and plaque buildup in coronary vessels from dyslipidemias, further reducing CHD incidence.<xref ref-type="bibr" rid="article-148894.r29">[29]</xref><xref ref-type="bibr" rid="article-148894.r30">[30]</xref></p>
        <p>
<bold>Bile Acid Sequesterants</bold>
<xref ref-type="bibr" rid="article-148894.r31">[31]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cholestyramine</p>
          </list-item>
          <list-item>
            <p>Colestipol</p>
          </list-item>
          <list-item>
            <p>Colesevelam</p>
          </list-item>
        </list>
        <p>Bile acid sequestrants exert their mechanistic effects by decreasing LDL-C absorption in the gastrointestinal tract, further causing its excretion in feces.&#x000a0;The sequestrants create an insoluble complex that is not digestible or can be reabsorbed, further depleting bile acids from circulation.&#x000a0;The excretion of bile acids initiates more cholesterol in the liver to be converted to bile acids, upregulating LDL receptors in the liver and decreasing plasma LDL-C in circulation.<xref ref-type="bibr" rid="article-148894.r31">[31]</xref></p>
        <p>
<bold>PCSK9 Inhibitors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Evolocumab</p>
          </list-item>
          <list-item>
            <p>Alirocumab</p>
          </list-item>
          <list-item>
            <p>Inclisiran<xref ref-type="bibr" rid="article-148894.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is a vital regulator of cholesterol. Mutations in PCSK9 result in a gain of function action, further increasing cholesterol in circulation and etiology for autosomal dominant familial hypercholesterolemia. PCSK9 inhibitors exert their mechanism of action by inhibiting PCSK9 receptors, which reduce LDL-C. The role of PCSK9 is to inhibit LDL receptor recycling which further increases LDL-C in circulation.</p>
        <p>Inhibiting the PCSK9 protein halts the inhibitory LDL receptor recycling effect, increasing hepatic LDL receptors, further increasing cholesterol uptake from circulation, and decreasing plasma LDL-C levels.&#x000a0;When patients fail to achieve LDL-C targets despite receiving statin and ezetimibe therapy at maximum doses, PCSK9 inhibitors should be considered an additional treatment option.<xref ref-type="bibr" rid="article-148894.r33">[33]</xref><xref ref-type="bibr" rid="article-148894.r32">[32]</xref><xref ref-type="bibr" rid="article-148894.r34">[34]</xref></p>
        <p>
<bold>Adenosine Triphosphate-citrate Lyase (ACL) Inhibitor</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bempedoic acid<xref ref-type="bibr" rid="article-148894.r35">[35]</xref></p>
          </list-item>
        </list>
        <p>Bemploic acid exerts its mechanism of action by inhibiting adenosine triphosphate-citrate lyase. The agent is a prodrug that acts in the liver once recognized by the enzyme acyl-CoA-synthetase-1 and converted to its active form, bempedoyl-CoA, further inhibiting ACL. It is FDA approved for heterozygous familial hypercholesterolemia and patients with ASVD who require additional management for decreasing LDL-C.<xref ref-type="bibr" rid="article-148894.r35">[35]</xref></p>
        <p>
<bold>Others</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Niacin</p>
          </list-item>
          <list-item>
            <p>Ezetimibe</p>
          </list-item>
          <list-item>
            <p>Omega-3 fatty acids (fish oil)</p>
          </list-item>
          <list-item>
            <p>Lomitapide</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148894.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Familial combined hyperlipidemia&#x000a0;has a broad range of differential diagnoses, as many hereditary and non-genetic etiologies cause increases in serum lipids.<xref ref-type="bibr" rid="article-148894.r26">[26]</xref></p>
        <p>Genetic dyslipidemias include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Familial hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Abetalipoproteinemia.</p>
          </list-item>
          <list-item>
            <p>Hypobetalipoproteinemia.</p>
          </list-item>
          <list-item>
            <p>Chylomicron retention disease</p>
          </list-item>
          <list-item>
            <p>Hypertriglyceridemia</p>
          </list-item>
        </list>
        <p>FCH may present with more subordinate total serum cholesterol levels and LDL-C than familial hypercholesterolemia.<xref ref-type="bibr" rid="article-148894.r1">[1]</xref>&#x000a0;This may be due to the complete expression of FCH transpiring in adulthood. However, the risk of early onset of atherosclerosis is equivalent in both dyslipidemias.&#x000a0;Early onset atherosclerosis is multifactorial when considering lipid and non-lipid characteristics such as insulin resistance and inadequate glucose metabolism, fatty liver, HTN, increased uric acid levels, and increased inflammatory markers in circulation.</p>
      </sec>
      <sec id="article-148894.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of FCH depends on several factors, including the age of onset, the severity of lipid abnormalities, comorbidities, and treatment adherence. FCH is associated with an increased risk of premature atherosclerotic cardiovascular disease (ASCVD), leading to significant morbidity and mortality if left untreated.</p>
        <p>To date, no appropriately designed trials have been conducted to determine the unique risk of cardiovascular disease among patients with familial combined hyperlipidemia. However, some authors propose that their risk may be at least as high as that of patients with heterozygous familial hypercholesterolemia.<xref ref-type="bibr" rid="article-148894.r36">[36]</xref></p>
      </sec>
      <sec id="article-148894.s11" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Atherosclerosis</bold>
</p>
        <p>Familial combined hyperlipidemia is linked to a higher likelihood of developing atherosclerosis. While some patients may not experience any symptoms, evaluating the intima-media thickness of the common carotid artery can serve as a means of estimating the risk.<xref ref-type="bibr" rid="article-148894.r37">[37]</xref></p>
        <p>
<bold>Coronary Artery Disease</bold>
</p>
        <p>A significant association exists between familial combined hyperlipidemia and an elevated coronary artery disease (CAD) risk.<xref ref-type="bibr" rid="article-148894.r36">[36]</xref><xref ref-type="bibr" rid="article-148894.r38">[38]</xref>&#x000a0;Notably, males with familial combined hyperlipidemia exhibit a higher prevalence of CAD than females, irrespective of their lipid profiles and other risk factors.<xref ref-type="bibr" rid="article-148894.r39">[39]</xref></p>
        <p>
<bold>Myocardial Infarction</bold>
</p>
        <p>Familial combined hyperlipidemia ranks high among the common causes of myocardial infarction in young people. In a study by Wiesbauer et al, the prevalence of FCH was 38% among patients&#x000a0;younger than 40.<xref ref-type="bibr" rid="article-148894.r40">[40]</xref></p>
      </sec>
      <sec id="article-148894.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Physicians should explain the genetic basis of FCH and how it is inherited in families. By understanding the genetic basis of the condition, patients can better understand their risk of developing cardiovascular disease and the importance of early intervention. In addition to genetic counseling,&#x000a0;patients should be educated on lifestyle modifications that can help manage FCH. This includes proper diet, regular exercise, and weight management. In addition, other modifiable risk factors should be addressed, such as smoking cessation, alcohol consumption, and stress management.</p>
        <p>Furthermore,&#x000a0;medications may be prescribed to help reduce cholesterol levels and decrease heart disease risk in patients with FCH. It is essential to discuss medication use's potential benefits and risks with their patients and monitor for any adverse effects. Regular follow-up appointments should be scheduled to monitor the patient's progress and adjust the treatment plan. Ongoing support and education help patients manage FCH effectively and maintain their overall health.</p>
      </sec>
      <sec id="article-148894.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>FCH is an inherited disorder characterized by abnormal lipid accumulation in the circulation, which can lead to cardiovascular disease and associated complications. Effective management of FCH requires close communication and care coordination among the interprofessional healthcare team, including the primary care clinician, cardiologist, nurse, pharmacist, and mid-level providers.</p>
        <p>As part of preventive care, the primary care team should conduct lipid screening to evaluate serum cholesterol levels in accordance with the guidelines provided by the United States Preventive Services Task Force (USPSTF). Additionally, they should assess contributing risk factors for coronary artery disease (CAD) and myocardial infarction, such as hypertension and diabetes. Earlier screening and diagnostic assessments may be warranted in patients at higher risk or with a family history of FCH. Comprehensive patient history should also be obtained, focusing on familial dyslipidemias or family history of heart disease.</p>
        <p>The primary care provider should discuss preventative measures and healthy lifestyle strategies with patients, including weight loss, dietary modifications, smoking cessation, alcohol use, and routine exercise. Early goal-directed therapy with first-line statin treatment is recommended for patients with FCH. Patients with uncontrolled hyperlipidemia and underlying comorbidities, such as prior CAD, hypertension, and diabetes, who are at risk for adverse cardiovascular events, may benefit from specialty care provided by cardiologists or endocrinologists for a more comprehensive management plan.<xref ref-type="bibr" rid="article-148894.r41">[41]</xref></p>
        <p>Patient education on FCH is an essential responsibility of the interprofessional team, including primary care providers, specialists, and healthcare professionals such as advanced practice practitioners. This education aims to enhance patient understanding of the disease, improve communication between patients and healthcare providers, and ensure continuity of care, leading to improved outcomes for individuals with genetic dyslipidemia.</p>
      </sec>
      <sec id="article-148894.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148894&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148894">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/familial-combined-hyperlipidemia-elevated-cholesterol/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=148894">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148894/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148894">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148894.s15">
        <title>References</title>
        <ref id="article-148894.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaverkov&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kar&#x000e1;sek</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Familial combined hyperlipidemia - the most common genetic dyslipidemia in population and in patients with premature atherothrombotic cardiovascular disease].</article-title>
            <source>Vnitr Lek</source>
            <year>2018</year>
            <season>Winter</season>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-29</page-range>
            <pub-id pub-id-type="pmid">29498872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veerkamp</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bredie</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hendriks</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Demacker</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2002</year>
            <month>Feb</month>
            <day>01</day>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>274</fpage>
            <page-range>274-82</page-range>
            <pub-id pub-id-type="pmid">11834528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taghizadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mardani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rostami</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taghizadeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bazireh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hayat</surname>
                <given-names>SMG</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review.</article-title>
            <source>J Cell Biochem</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>120</volume>
            <issue>6</issue>
            <fpage>8891</fpage>
            <page-range>8891-8898</page-range>
            <pub-id pub-id-type="pmid">30556165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bello-Chavolla</surname>
                <given-names>OY</given-names>
              </name>
              <name>
                <surname>Kuri-Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000ed;os-R&#x000ed;os</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vargas-V&#x000e1;zquez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cort&#x000e9;s-Arroyo</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tapia-Gonz&#x000e1;lez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cruz-Bautista</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aguilar-Salinas</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES.</article-title>
            <source>Rev Invest Clin</source>
            <year>2018</year>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>224</fpage>
            <page-range>224-236</page-range>
            <pub-id pub-id-type="pmid">30307446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trinder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vikulova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pimstone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>GBJ</given-names>
              </name>
              <name>
                <surname>Brunham</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.</article-title>
            <source>Atherosclerosis</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>340</volume>
            <fpage>35</fpage>
            <page-range>35-43</page-range>
            <pub-id pub-id-type="pmid">34906840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taghizadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Esfehani</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sahebkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parizadeh</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rostami</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mirinezhad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poursheikhani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mobarhan</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pasdar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies.</article-title>
            <source>IUBMB Life</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>9</issue>
            <fpage>1221</fpage>
            <page-range>1221-1229</page-range>
            <pub-id pub-id-type="pmid">31271707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaddi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cicero</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Odoo</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Poli</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>R</given-names>
              </name>
              <collab>Atherosclerosis and Metabolic Diseases Study Group</collab>
            </person-group>
            <article-title>Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2007</year>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>877</fpage>
            <page-range>877-86</page-range>
            <pub-id pub-id-type="pmid">18200807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Fibrate Medications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31613536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pahan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Lipid-lowering drugs.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2006</year>
            <month>May</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>1165</fpage>
            <page-range>1165-78</page-range>
            <pub-id pub-id-type="pmid">16568248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schrott</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Hazzard</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Bierman</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Motulsky</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.</article-title>
            <source>J Clin Invest</source>
            <year>1973</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>7</issue>
            <fpage>1544</fpage>
            <page-range>1544-68</page-range>
            <pub-id pub-id-type="pmid">4718953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paramsothy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knopp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Rue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Heckbert</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis.</article-title>
            <source>Metabolism</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>212</fpage>
            <page-range>212-9</page-range>
            <pub-id pub-id-type="pmid">19154954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Himbergen</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Otokozawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matthan</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Buchsbaum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Tits</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-20</page-range>
            <pub-id pub-id-type="pmid">19834104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badzioch</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Igo</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brunzell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Motulsky</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wijsman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Jarvik</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>10</issue>
            <fpage>1942</fpage>
            <page-range>1942-50</page-range>
            <pub-id pub-id-type="pmid">15331429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pajukanta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Sinsheimer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lusis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Soro-Paavonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naukkarinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saarela</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laakso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ehnholm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1).</article-title>
            <source>Nat Genet</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-6</page-range>
            <pub-id pub-id-type="pmid">14991056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taghizadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mirzaei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jalilian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghayour Mobarhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferns</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Pasdar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A novel mutation in USF1 gene is associated with familial combined hyperlipidemia.</article-title>
            <source>IUBMB Life</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>616</fpage>
            <page-range>616-623</page-range>
            <pub-id pub-id-type="pmid">31725952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro Cabezas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Bruin</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>de Valk</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Shoulders</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Willem Erkelens</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.</article-title>
            <source>J Clin Invest</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>160</fpage>
            <page-range>160-8</page-range>
            <pub-id pub-id-type="pmid">8100834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aulchenko</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Ripatti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindqvist</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boomsma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heid</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Pramstaller</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Penninx</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kyvik</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Kaprio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freimer</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Jarvelin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gyllensten</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rudan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marroni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vitart</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jonasson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pattaro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hastie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pichler</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Falchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Willemsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hottenga</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>de Geus</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Whitfield</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saharinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silander</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sijbrands</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Uitterlinden</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Witteman</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Oostra</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruokonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sabatti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gieger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meitinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kronenberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D&#x000f6;ring</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wichmann</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>van Duijn</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>L</given-names>
              </name>
              <collab>ENGAGE Consortium</collab>
            </person-group>
            <article-title>Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.</article-title>
            <source>Nat Genet</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-55</page-range>
            <pub-id pub-id-type="pmid">19060911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taghizadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghayour-Mobarhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferns</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Pasdar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A novel variant in LPL gene is associated with familial combined hyperlipidemia.</article-title>
            <source>Biofactors</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <page-range>94-99</page-range>
            <pub-id pub-id-type="pmid">31599081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Civeira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jarauta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cenarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Ot&#x000ed;n</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tejedor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zamb&#x000f3;n</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pocov&#x000ed;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2008</year>
            <month>Nov</month>
            <day>04</day>
            <volume>52</volume>
            <issue>19</issue>
            <fpage>1546</fpage>
            <page-range>1546-53</page-range>
            <pub-id pub-id-type="pmid">19007590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brouwers</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Himbergen</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Otokozawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Troutt</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>van Greevenbroek</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.</article-title>
            <source>Nutr Metab Cardiovasc Dis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1115</fpage>
            <page-range>1115-21</page-range>
            <pub-id pub-id-type="pmid">23333725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Brunzell</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>2601</fpage>
            <page-range>2601-7</page-range>
            <pub-id pub-id-type="pmid">15181030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maharaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia presenting with multiple nodules of the hands and elbow.</article-title>
            <source>Clin Case Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-4</page-range>
            <pub-id pub-id-type="pmid">26185639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slaby</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vecka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Xanthomas: clinical and pathophysiological relations.</article-title>
            <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>158</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-8</page-range>
            <pub-id pub-id-type="pmid">24781043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Junyent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zamb&#x000f3;n</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilabert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cof&#x000e1;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>N&#x000fa;&#x000f1;ez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Carotid atherosclerosis in familial combined hyperlipidemia associated with the APOB/APOA-I ratio.</article-title>
            <source>Atherosclerosis</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>197</volume>
            <issue>2</issue>
            <fpage>740</fpage>
            <page-range>740-6</page-range>
            <pub-id pub-id-type="pmid">17698072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keulen</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Kruijshoop</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaper</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Hoeks</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>de Bruin</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2002</year>
            <month>Feb</month>
            <day>01</day>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>283</fpage>
            <page-range>283-8</page-range>
            <pub-id pub-id-type="pmid">11834529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parhofer</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>The Treatment of Disorders of Lipid Metabolism.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2016</year>
            <month>Apr</month>
            <day>15</day>
            <volume>113</volume>
            <issue>15</issue>
            <fpage>261</fpage>
            <page-range>261-8</page-range>
            <pub-id pub-id-type="pmid">27151464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bansal</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>HMG-CoA Reductase Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31194369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tricarico</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Crovella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Celsi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible Link.</article-title>
            <source>Int J Mol Sci</source>
            <year>2015</year>
            <month>Jul</month>
            <day>15</day>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>16067</fpage>
            <page-range>16067-84</page-range>
            <pub-id pub-id-type="pmid">26184189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mathew</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Fibric Acid Antilipemic Agents</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">30860743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of fibrates.</article-title>
            <source>Postgrad Med J</source>
            <year>1993</year>
            <volume>69 Suppl 1</volume>
            <fpage>S34</fpage>
            <page-range>S34-41</page-range>
            <pub-id pub-id-type="pmid">8497455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Lent-Schochet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Antilipemic Agent Bile Acid Sequestrants</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">31751096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pokhrel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pellegrini</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <chapter-title>PCSK9 Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28846236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomlinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Fok</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CWK</given-names>
              </name>
            </person-group>
            <article-title>Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-295</page-range>
            <pub-id pub-id-type="pmid">33866776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handelsman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lepor</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2018</year>
            <month>Jun</month>
            <day>22</day>
            <volume>7</volume>
            <issue>13</issue>
            <pub-id pub-id-type="pmid">29934421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bempedoic Acid: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>May</month>
            <volume>80</volume>
            <issue>7</issue>
            <fpage>747</fpage>
            <page-range>747-753</page-range>
            <pub-id pub-id-type="pmid">32314225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skoumas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Masoura</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pitsavos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tousoulis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papadimitriou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aznaouridis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chrysohoou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giotsas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Toutouza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tentolouris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antoniades</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stefanadis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.</article-title>
            <source>Int J Cardiol</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-83</page-range>
            <pub-id pub-id-type="pmid">17188767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halenka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaverkova</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hutyra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karasek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slavik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krskova</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Detection of early atherosclerosis using the ultrasound parameter of the intima-media thickness of the common carotid artery in families with familial combined hyperlipidemia.</article-title>
            <source>Int Angiol</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>230</fpage>
            <page-range>230-7</page-range>
            <pub-id pub-id-type="pmid">15765037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voors-Pette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Bruin</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity.</article-title>
            <source>Atherosclerosis</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>157</volume>
            <issue>2</issue>
            <fpage>481</fpage>
            <page-range>481-9</page-range>
            <pub-id pub-id-type="pmid">11472750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitsavos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Skoumas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Masoura</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aznaouridis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Papadimitriou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chrysohoou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giotsas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Toutouza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stefanadis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia.</article-title>
            <source>Atherosclerosis</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>199</volume>
            <issue>2</issue>
            <fpage>402</fpage>
            <page-range>402-7</page-range>
            <pub-id pub-id-type="pmid">18164018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiesbauer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blessberger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Azar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goliasch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gerhold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Widhalm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abdolvahab</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sodeck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schillinger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Familial-combined hyperlipidaemia in very young myocardial infarction survivors (&#x0003c; or =40 years of age).</article-title>
            <source>Eur Heart J</source>
            <year>2009</year>
            <month>May</month>
            <volume>30</volume>
            <issue>9</issue>
            <fpage>1073</fpage>
            <page-range>1073-9</page-range>
            <pub-id pub-id-type="pmid">19276196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148894.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Helfand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <source>Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2008</year>
            <month>06</month>
            <pub-id pub-id-type="pmid">20722146</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
